These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 270373

  • 1. Assessment of drug sensitivity of human leukaemic myeloblasts. II. The toxic effects of cytosine arabinoside on 125IUdR-labelled human leukaemic myeloblasts in mice.
    Sonis ST, Falcão R, MacLennan IC.
    Br J Cancer; 1977 Sep; 36(3):307-12. PubMed ID: 270373
    [Abstract] [Full Text] [Related]

  • 2. Assessment of drug sensitivity of human leukaemic myeloblasts. I. Labelling human myeloblasts with 125IUdR for survival studies in mice.
    Falcão RP, Sonis S, MacLennan IC, Chassoux D, Davies AJ, Munro TR.
    Br J Cancer; 1977 Sep; 36(3):297-306. PubMed ID: 270372
    [Abstract] [Full Text] [Related]

  • 3. Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy.
    Harris AL, Grahame-Smith DG, Potter CG, Bunch C.
    Clin Sci (Lond); 1981 Feb; 60(2):191-8. PubMed ID: 6940687
    [Abstract] [Full Text] [Related]

  • 4. Cell proliferation and protein synthesis in human leukaemic myeloblasts after cytosine arabinoside therapy.
    Wantzin GL, Karle H, Killmann SA.
    Br J Haematol; 1976 Feb; 32(2):283-9. PubMed ID: 1061618
    [Abstract] [Full Text] [Related]

  • 5. Perturbation of cell cycle of human leukaemic myeloblasts in vivo by cytosine arabinoside.
    Ernst P, Faille A, Killmann SA.
    Scand J Haematol; 1973 Feb; 10(3):209-18. PubMed ID: 4520466
    [No Abstract] [Full Text] [Related]

  • 6. Effects of cytosine arabinoside on unseparated bone marrow and peripheral blood cells and on specimens enriched for myeloblasts and promyelocytes.
    Epstein J, Preisler HD, Rustum YM, Higby DJ.
    Exp Hematol; 1980 Apr; 8(4):404-8. PubMed ID: 7461048
    [Abstract] [Full Text] [Related]

  • 7. Low dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction.
    Leyden M, Manoharan A, Boyd A, Cheng ZM, Sullivan J.
    Br J Haematol; 1984 Jun; 57(2):301-7. PubMed ID: 6587903
    [Abstract] [Full Text] [Related]

  • 8. In vivo differentiation of leukaemic blasts and effect of low dose Ara-C in a marrow grafted patient with leukaemic relapse.
    Mittermüller J, Kolb HJ, Gerhartz HH, Wilmanns W.
    Br J Haematol; 1986 Apr; 62(4):757-62. PubMed ID: 2938618
    [Abstract] [Full Text] [Related]

  • 9. Small doses of ARA-C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?
    Housset M, Daniel MT, Degos L.
    Br J Haematol; 1982 May; 51(1):125-9. PubMed ID: 6951603
    [Abstract] [Full Text] [Related]

  • 10. The relationship of Ara-C metabolism in vitro to therapeutic response in acute myeloid leukaemia.
    Harris AL, Grahame-Smith DG.
    Cancer Chemother Pharmacol; 1982 May; 9(1):30-5. PubMed ID: 6958391
    [Abstract] [Full Text] [Related]

  • 11. Surface antigens in acute myeloblastic leukaemia: a study using heterologous antisera.
    Tupchong L, MacLennan IC.
    Br J Cancer; 1978 Oct; 38(4):481-95. PubMed ID: 281967
    [Abstract] [Full Text] [Related]

  • 12. In vitro culture of clonogenic leukaemic cells in acute myeloid leukaemia: growth pattern and drug sensitivity.
    Marie JP, Zittoun R, Thevenin D, Mathieu M, Viguie F.
    Br J Haematol; 1983 Nov; 55(3):427-37. PubMed ID: 6580036
    [Abstract] [Full Text] [Related]

  • 13. Arabinosyl cytosine in chronic myeloid leukaemia: evidence for high cytokinetic sensitivity of myeloblasts.
    Baccarani M, Santucci AM, Tura S, Killmann SA.
    Scand J Haematol; 1976 May; 16(5):335-52. PubMed ID: 1065953
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
    Yang GS, McCulloch EA.
    Hematol Pathol; 1992 May; 6(3):125-30. PubMed ID: 1385380
    [Abstract] [Full Text] [Related]

  • 17. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood.
    Kaspers GJ, Pieters R, Van Zantwijk CH, De Laat PA, De Waal FC, Van Wering ER, Veerman AJ.
    Br J Cancer; 1991 Sep; 64(3):469-74. PubMed ID: 1911186
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside.
    Tattersall MH, Ganeshaguru K, Hoffbrand AV.
    Br J Haematol; 1974 May; 27(1):39-46. PubMed ID: 4368900
    [No Abstract] [Full Text] [Related]

  • 19. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin.
    Taub JW, Stout ML, Buck SA, Huang X, Vega RA, Becton DL, Ravindranath Y.
    Leukemia; 1997 Sep; 11(9):1594-5. PubMed ID: 9305619
    [No Abstract] [Full Text] [Related]

  • 20. Nuclear DNA-polymerase estimation in human leukaemic myeloblasts.
    Wantzin GL, Karle H, Killmann SA.
    Br J Haematol; 1976 Jul; 33(3):329-34. PubMed ID: 1064433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.